Financials

Company Profile

Scorpius Holdings, Inc. is not engaged in any business activities. The Company was previously a contract development and manufacturing organization.

Employees

Sector

Date	Price	Change	Volume
21/08/26	$0.001000	0.00%	3,865
20/08/26	$0.001000	0.00%	12,003
14/08/26	$0.001000	0.00%	75,684

Delayed Quote OTC Markets

Delayed OTC Markets 17:30:19 21/08/2026 +04			5-day change	1st Jan Change
0.001000 ^USD	0.00%		0.00%	+400.00%

04-25	Scorpius Holdings, Inc. Announces Board and Committee Changes	CI
04-08	Scorpius Holdings, Inc. Announces Resignation of William Ostrander as Chief Financial Officer, Effective March 31, 2026	CI

04-25	Scorpius Holdings, Inc. Announces Board and Committee Changes	CI
04-08	Scorpius Holdings, Inc. Announces Resignation of William Ostrander as Chief Financial Officer, Effective March 31, 2026	CI
03-11	Scorpius Holdings, Inc. announced that it has received $0.031175 million in funding	CI
02-26	Scorpius Holdings, Inc. announced that it has received $0.219544 million in funding	CI
02-18	Scorpius Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
02-12	Scorpius Holdings, Inc. announced that it has received $0.030427 million in funding	CI
01-13	Scorpius Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12-16	Scorpius Holdings, Inc. announced that it has received $0.044374 million in funding	CI
12-11	Velocity Bioworks, Inc. acquired All of Personal Property and Assets of Scorpius Holdings, Inc. for $16.3 million.	CI
12-03	Scorpius Holdings, Inc. Announces Issuance of Multiple Non-Convertible Promissory Notes with Customary Terms	CI
12-01	Scorpius Holdings, Inc. announced that it has received $0.1541 million in funding	CI
11-26	Scorpius Holdings, Inc. announced that it has received $0.724523 million in funding	CI
11-25	Scorpius Holdings, Inc. announced that it has received $0.03795 million in funding	CI

01/05/23	Brookline Capital Downgrades NightHawk Biosciences to Hold From Buy	MT
03/04/23	Maxim Downgrades NightHawk Biosciences to Hold From Buy	MT
18/03/22	B. Riley Lowers Heat Biologics' PT to $8 from $10, Adjusts Model for Higher Cost of Capital to Support Higher Operating Expenditures Ramp; Keeps Buy Rating	MT
15/03/22	Alliance Global Adjusts Heat Biologics' Price Target to $15.50 From $20, Reiterates Buy Rating	MT
24/01/22	B. Riley Lowers Heat Biologics' Price Target to $10 from $15 After Revising Cost Capital Assumptions, Keeps Buy Rating	MT

01-13	Scorpius : Quarterly Report for Quarter Ending June 30, 2025 (Form 10-Q)	PU
15/11/24	Scorpius : Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability Form 8 K	PU
22/10/24	Scorpius Holdings Announces Partnership with U.S. Biotech Company	AQ
02/10/24	Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats	AQ
30/09/24	Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities	AQ

Manager	Title	Age	Since
Jeff Wolf CEO	Chief Executive Officer	63	01/04/2010
Joe Payne COO	Chief Operating Officer	-	-
David Waldman IRC	Investor Relations Contact	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/05/24	Jeff Wolf	Free	Chief Executive Officer	5,000,000	13.8766%
16/05/24	Seed-One Ventures LLC	Other	Company	0	0%
16/05/24	Orion Holdings LLC	Other	Company	0	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCORPIUS HOLDINGS, INC.	0.00%	0.00%	-90.91%	-100.00%	61.14K
CHURCHILL CAPITAL CORP XI	+2.52%	-14.82%	-	-	784M
CENTIEL AG	-7.45%	-9.01%	+280.00%	-72.39%	713M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	+0.20%	-	-	646M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.39%	+0.29%	-	-	603M
CHURCHILL CAPITAL CORP XII	-0.74%	-0.33%	-	-	600M
CANTOR EQUITY PARTNERS IV, INC.	-0.48%	-0.77%	-	-	594M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	+0.69%	+1.39%	-	-	575M
CHURCHILL CAPITAL CORP XIII	0.00%	+0.67%	-	-	508M
Average	-0.65%	-1.59%	+94.55%	-86.20%	557.94M
Weighted average by Cap.	-0.78%	-2.22%	+279.97%	-72.40%